Mark Leonard, PhD

Pri­or to join­ing Metageno­mi, Mark served as Vice Pres­i­dent, Process and Prod­uct Devel­op­ment at Allo­gene Ther­a­peu­tics, where he built the team from the ground up and had broad account­abil­i­ty for devel­op­ment and man­u­fac­tur­ing support/​MSAT activ­i­ties in the deliv­ery of Allogene’s nov­el allo­gene­ic CAR T cell ther­a­py prod­ucts — from cell start­ing mate­r­i­al to CAR T cell drug prod­uct, includ­ing gene-edit­ing mRNAs and lentivi­ral vec­tor drug sub­stance and their ​“com­pan­ion” lym­phode­ple­tion anti­body. Pri­or to Allo­gene, Mark was Exec­u­tive Direc­tor of Cell and Gene Ther­a­py Tech­ni­cal Devel­op­ment in the Bio­ther­a­peu­tics Phar­ma­ceu­ti­cal Sci­ences orga­ni­za­tion at Pfiz­er, and held posi­tions of increas­ing respon­si­bil­i­ty at Wyeth/​Genet­ics Institute.

Mark holds a Ph.D. in Mol­e­c­u­lar Biol­o­gy from the Uni­ver­si­ty of Lon­don, King’s Col­lege, Dept. of Bio­physics and was a Leukemia Soci­ety of Amer­i­ca Post­doc­tor­al Fel­low at North­west­ern Uni­ver­si­ty, Evanston, IL.